| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cancer Diagnostics |
1 Research and Development Division, Fujirebio Diagnostics, Inc., Malvern, PA.
aAddress correspondence to this author at: Research and Development Division, Fujirebio Diagnostics, Inc., 201 Great Valley Pkwy., Malvern, PA 19355. Fax 610-240-3803; e-mail allardj{at}fdi.com.
Background: Soluble mesothelin-related peptides (SMRP)have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM). We report analytical and preliminary clinical studies of MESOMARKTM, a quantitative assay for SMRP.
Methods: The MESOMARK assay is a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve (0–32 nmol/L). We assessed analytical imprecision, analyte stability, and analytical interferences. We measured SMRP by this assay in 409 apparently healthy individuals (reference interval study), 177 patients with nonmalignant conditions, and 500 cancer patients, including 88 with MPM.
Results: The limit of detection was 0.16 nmol/L. At 2–19 nmol/L, intraassay imprecision (CV) was 1.1%–5.3%, and total imprecision was 4.0%–11.0%. The mean dilution recovery for 5 samples was 109% (range, 99%–113%). No interference was seen from added bilirubin (200 mg/L), hemoglobin (500 mg/L), triglycerides (30 g/L), chemotherapeutic agents, or other tested substances. Recombinant mesothelin was stable in serum upon freeze/thaw at –70 °C and upon storage for at least 7 days at 2–8 °C. The 99th percentile of the reference group was 1.5 nmol/L [95% confidence interval (CI), 1.2–1.6 nmol/L; n = 409], and mean SMRP was significantly higher in sera from patients with MPM (7.5 nmol/L; 95% CI, 2.8–12.1 nmol/L; n = 88). SMRP was increased in 52% and 5% of MPM patients and asbestos-exposed individuals, respectively. Concentrations in other nonmalignant and malignant conditions were similar to those in healthy controls.
Conclusions: The MESOMARK assay is analytically robust and may be useful for the detection and management of mesothelioma.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  F. Mc. Johnston, M. C.B. Tan, B. R. Tan Jr., M. R. Porembka, E. M. Brunt, D. C. Linehan, P. O. Simon Jr., S. Plambeck-Suess, T. J. Eberlein, K. E. Hellstrom, et al. Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer Clin. Cancer Res., November 1, 2009; 15(21): 6511 - 6518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ray and H. L. Kindler Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment Chest, September 1, 2009; 136(3): 888 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hollevoet, D. Bernard, F. De Geeter, N. Walgraeve, A. Van den Eeckhaut, R. Vanholder, C. Van de Wiele, V. Stove, J. P. van Meerbeeck, and J. R. Delanghe Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum Clin. Chem., July 1, 2009; 55(7): 1431 - 1433. [Full Text] [PDF]
|
|
|
|
 |
|
 P M Lindholm, Y Soini, M Myllarniemi, S Knuutila, M Heikinheimo, V L Kinnula, and K Salmenkivi Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma J. Clin. Pathol., April 1, 2009; 62(4): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rodriguez Portal, E. Rodriguez Becerra, D. Rodriguez Rodriguez, I. Alfageme Michavila, A. Quero Martinez, C. Diego Roza, A. Leon Jimenez, I. Isidro Montes, and P. Cebollero Rivas Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 646 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-K. Park, A. Sandrini, D. H. Yates, J. Creaney, B. W. Robinson, P. S. Thomas, and A. R. Johnson Soluble Mesothelin-related Protein in an Asbestos-exposed Population: The Dust Diseases Board Cohort Study Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 832 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. An, D. C. Drummond, S. Wilson, D. B. Kirpotin, S. L. Nishimura, V. C. Broaddus, and B. Liu Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies Mol. Cancer Ther., March 1, 2008; 7(3): 569 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cristaudo, R. Foddis, A. Vivaldi, G. Guglielmi, N. Dipalma, R. Filiberti, M. Neri, M. Ceppi, M. Paganuzzi, G. P. Ivaldi, et al. Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer Clin. Cancer Res., September 1, 2007; 13(17): 5076 - 5081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y C G. Lee Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax, July 1, 2007; 62(7): 561 - 562. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
